Related Experiment Video

Updated: Feb 16, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus

Shilpa Vijayakumar1, Muthiah Vaduganathan2, Javed Butler3

  • 1a Department of Medicine , Stony Brook University , Stony Brook , NY , USA.

Expert Review of Cardiovascular Therapy
|January 4, 2018
PubMed

Insights

Type 2 diabetes mellitus (DM) and heart failure (HF) are linked, with one worsening the other. Current glucose-lowering therapies

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (DM) and heart failure (HF) share a strong bidirectional relationship, where each condition independently exacerbates the other.
  • The complex interplay and full clinical impact of comorbid DM and HF remain incompletely understood.
  • Glucose-lowering therapies exhibit varied cardiovascular effects, necessitating formal evaluation of their impact on heart failure outcomes.

Purpose of the Study:

  • To evaluate the ascertainment and availability of heart failure (HF) outcome data in contemporary cardiovascular outcome trials (CVOTs) of glucose-lowering therapies.
  • To highlight the increasing recognition of HF events as critical endpoints in trials for type 2 diabetes treatments.

Main Methods:

  • A comprehensive literature search was conducted on recent cardiovascular outcome trials (CVOTs) involving glucose-lowering therapies.
  • Analysis focused on the methods and extent of data collection for heart failure outcomes within these trials.

Main Results:

  • Heart failure outcomes were not a primary focus in earlier cardiovascular outcome trials.
  • Contemporary trials increasingly incorporate HF events as significant endpoints.
  • There is variability in the ascertainment and standardization of HF data across trials.

Conclusions:

  • Heart failure outcomes are crucial endpoints in evaluating glucose-lowering therapies for patients with type 2 diabetes.
  • Standardized and routine ascertainment of HF data in clinical trials is essential for better understanding treatment effects.
  • Improved data collection will enhance clinical decision-making for managing patients with both DM and HF.
Abstract

Keywords:
Diabetes mellitusheart failureoutcomes

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.6K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

666

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402